Abstract
Alpha1-antitrypsin Deficiency (AATD) is a rare hereditary disorder with an estimated prevalence of about 1/5000 individuals in Italy. Deficient patients are at a higher risk of developing lung emphysema and chronic liver disease. The low estimated prevalence of AATD prompted the establishment of a registry with the aim of learning more about the natural history and the quality of care of these patients. The Italian registry for AATD was established in 1996. In this study, genetic and clinical findings of Italian AATD patients are presented. Moreover, we also evaluated the changes in health-related quality of life (HRQoL) in patients with COPD and AAT deficiency over a three-year period, in relation to augmentation therapy.
In a period spanning 18 years (1996–2014) a total of 422 adult subjects with severe AATD were enrolled, namely 258 PI*ZZ, 74 PI*SZ, 4 PI*SS and 86 patients with at least one rare deficient allele. The 21.3% frequency for AATD patients with at least one deficient rare variant is the highest so far recorded in national registries of AATD. The registry data allow a detailed characterization of the natural course of the disease and the level of patient care, as well as confirm the usefulness of early AATD detection.
Acknowledgments
The authors are deeply indebted to all the physicians who participate in the Italian AATD screening program.
Funding
This study was supported by Grifols, the Fondazione IRCCS Policlinico San Matteo – Ricerca Corrente (RC345, RC721) and the Fondazione Salvatore Maugeri IRCCS - Ricerca Corrente.
Declaration of Interest
ML received consultancy fees from Grifols and participated in advisory boards sponsored by CSL Behring. IF received consultancy fees and travel support from Grifols. LC and BB received consultancy fees from Grifols. SO, CS and LI received travel support from Grifols.
All other authors have no conflicts of interest to declare. The authors alone are responsible for the content and writing of the paper.